Comparison of the Efficacy of Duloxetine Versus Pregabalin for Pain Relief of Neuropathy in Diabetics
DOI:
https://doi.org/10.36283/PJMD13-1/003Keywords:
Diabetes Mellitus, Diabetic Neuropathy, Duloxetine Hydrochloride, PregabalinAbstract
Background: Neuropathy is a common complication in diabetic patients with clinical manifestations of feet and hands paresthesia, pain in the lower legs, and a burning sensation in the soles. A wide variety of medications are used for diabetic neuropathy with varying degrees of pain relief reported. The study objective was to compare the efficacy of duloxetine versus pregabalin for pain relief of neuropathy in diabetics.
Methods: The study was a six-week, single-blind, Randomized Controlled Trial conducted at HBS Medical and Dental College and Hospital in Islamabad. Patients were randomly designated to either of the groups (A or B) with 50 participants in each group. Group A received 150mg of pregabalin twice a day while group B received 60mg of duloxetine once a day. Pain relief was the primary outcome which was considered as a ≥ 50% decrease in pain score on the Visual Analog Scale at 6 weeks from baseline.
Results: A total of 100 diabetic patients were registered in the study. The mean age in groups A&B was 48.36 and 50.56 SD± 6.64) years respectively. The majority of the study population were males 39 (78%) and 42 (84%) in both groups. A total of 66% (n=33) in Group A and 74% (n=37) of the patients in Group B achieved pain relief. A comparison of the pain relief achieved between the two groups showed no statistical significance (p-value 0.383).
Conclusion: The study revealed that duloxetine and pregabalin are both efficacious in terms of pain relief for diabetic neuropathy in our population.
References
Feldman EL, Callaghan BC, Pop-Busui R, Zochodne DW, Wright DE, Bennett DL, Bril V, Russell JW, Viswanathan V. Diabetic neuropathy. Nat Rev Dis Primers. 2019;5(1):41. doi: 10.1038/s41572-019-0092-1.
Frier BM, Fisher M. Diabetes mellitus. In: Colledge NR, Walker BR, Ralston SH (Editors). David's principles and practice of Medicine. 21sted.New Delhi: Elsevier Limited 2010; 796-834.
Akhtar S, Hassan F, Saqlain SR, Ali A, Hussain S. The prevalence of peripheral neuropathy among the patients with diabetes in Pakistan: a systematic review and meta-analysis. Sci Rep. 2023;13(1):11744. doi: 10.1038/s41598-023-39037-1.
Castelli G, Desai KM, Cantone RE. Peripheral Neuropathy: Evaluation and Differential Diagnosis. Am Fam Physician. 2020;102(12):732-739.
Tesfaye S. Advances in the management of diabetic peripheral neuropathy. Curr Opin Support Palliat Care. 2009;3(2):136-143. doi: 10.1097/SPC.0b013e32832b7df5.
Tesfaye S, Boulton AJ, Dickenson AH. Mechanisms and management of diabetic painful distal symmetrical polyneuropathy. Diabetes Care. 2013;36(9):2456-2465. doi: 10.2337/dc12-1964.
Wright A, Luedtke KE, Vandenberg C. Duloxetine in the treatment of chronic pain due to fibromyalgia and diabetic neuropathy. J Pain Res. 2010; 4:1-10. doi: 10.2147/JPR.S12866.
Kaur H, Hota D, Bhansali A, Dutta P, Bansal D, Chakrabarti A. A comparative evaluation of amitriptyline and duloxetine in painful diabetic neuropathy: a randomized, double-blind, cross-over clinical trial. Diabetes Care. 2011;34(4):818-822. doi: 10.2337/dc10-1793.
NICE Clinical Guideline 96: Neuropathic Pain. The pharmacological management of neuropathic pain in adults in non-specialist settings.2010.
Wu CS, Huang YJ, Ko YC, Lee CH. Efficacy and safety of duloxetine in painful diabetic peripheral neuropathy: a systematic review and meta-analysis of randomized controlled trials. Syst Rev. 2023;12(1):53. doi: 10.1186/s13643-023-02185-6.
Satoh J, Yagihashi S, Baba M, Suzuki M, Arakawa A, Yoshiyama T, Shoji S. Efficacy and safety of pregabalin for treating neuropathic pain associated with diabetic peripheral neuropathy: a 14 week, randomized, double-blind, placebo-controlled trial. Diabet Med. 2011 Jan;28(1):109-116. doi: 10.1111/j.1464-5491.2010.03152.x.
Bril V, England J, Franklin GM, Backonja M, Cohen J, Del Toro D, Feldman E, Iverson DJ, Perkins B, Russell JW, Zochodne D; American Academy of Neurology; American Association of Neuromuscular and Electrodiagnostic Medicine; American Academy of Physical Medicine and Rehabilitation. Evidence-based guideline: Treatment of painful diabetic neuropathy: report of the American Academy of Neurology, the American Association of Neuromuscular and Electrodiagnostic Medicine, and the American Academy of Physical Medicine and Rehabilitation. Neurology. 2011;76(20):1758-1765. doi: 10.1212/WNL.0b013e3182166ebe.
Vinik A. The approach to the management of the patient with neuropathic pain. J Clin Endocrinol Metab. 2010;95(11):4802-4811. doi: 10.1210/jc.2010-0892.
Armstrong DG, Chappell AS, Le TK, Kajdasz DK, Backonja M, D'Souza DN, Russell JM. Duloxetine for the management of diabetic peripheral neuropathic pain: evaluation of functional outcomes. Pain Med. 2007;8(5):410-418. doi: 10.1111/j.1526-4637.2007.00276.x.
Schreiber AK, Nones CF, Reis RC, Chichorro JG, Cunha JM. Diabetic neuropathic pain: Physiopathology and treatment. World J Diabetes. 2015;6(3):432-444. doi: 10.4239/wjd.v6.i3.432.
Pritchett YL, McCarberg BH, Watkin JG, Robinson MJ. Duloxetine for the management of diabetic peripheral neuropathic pain: response profile. Pain Med. 2007;8(5):397-409. doi: 10.1111/j.1526-4637.2007.00305.x.
Whitmyer VG, Dunner DL, Kornstein SG, Meyers AL, Mallinckrodt CH, Wohlreich MM, Gonzales JS, Greist JH. A comparison of initial duloxetine dosing strategies in patients with major depressive disorder. J Clin Psychiatry. 2007;68(12):1921-1930. doi: 10.4088/jcp.v68n1213.
Skljarevski V, Zhang S, Iyengar S, D'Souza D, Alaka K, Chappell A, Wernicke J. Efficacy of Duloxetine in Patients with Chronic Pain Conditions. Curr Drug ther. 2011;6(4):296-303. doi: 10.2174/157488511798109592.
Yang H, Sloan G, Ye Y, Wang S, Duan B, Tesfaye S, Gao L. New Perspective in Diabetic Neuropathy: From the Periphery to the Brain, a Call for Early Detection, and Precision Medicine. Front Endocrinol (Lausanne). 2020; 10:929. doi: 10.3389/fendo.2019.00929.
Shahid W, Kumar R, Shaikh A, Kumar S, Jameel R, Fareed S. Comparison of the Efficacy of Duloxetine and Pregabalin in Pain Relief Associated with Diabetic Neuropathy. Cureus. 2019;11(7):e5293. doi: 10.7759/cureus.5293.
Sultan A, Gaskell H, Derry S, Moore RA. Duloxetine for painful diabetic neuropathy and fibromyalgia pain: systematic review of randomised trials. BMC Neurol. 2008; 8:29. doi: 10.1186/1471-2377-8-29.
Wernicke JF, Wang F, Pritchett YL, Smith TR, Raskin J, D'Souza DN, Iyengar S, Chappell AS. An open-label 52-week clinical extension comparing duloxetine with routine care in patients with diabetic peripheral neuropathic pain. Pain Med. 2007;8(6):503-513. doi: 10.1111/j.1526-4637.2006.00258 x.
Shaheen A, Alam SM, Ahmad A, Khan M. Clinical efficacy and tolerability of Gabapentinoids with current prescription patterns in patients with Neuropathic pain. Pak J Med Sci. 2019;35(6):1505-1510. doi: 10.12669/pjms.35.6.652.
Devi P, Madhu K, Ganapathy B, Sarma G, John L, Kulkarni C. Evaluation of efficacy and safety of gabapentin, duloxetine, and pregabalin in patients with painful diabetic peripheral neuropathy. Indian J Pharmacol. 2012;44(1):51-56. doi: 10.4103/0253-7613.91867.
Tanenberg RJ, Irving GA, Risser RC, Ahl J, Robinson MJ, Skljarevski V, Malcolm SK. Duloxetine, pregabalin, and duloxetine plus gabapentin for diabetic peripheral neuropathic pain management in patients with inadequate pain response to gabapentin: an open-label, randomized, noninferiority comparison. Mayo Clin Proc. 2011;86(7):615-626. doi: 10.4065/mcp.2010.0681.
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Pakistan Journal of Medicine and Dentistry
This work is licensed under a Creative Commons Attribution 4.0 International License.
This is an open-access article distributed under the terms of the CreativeCommons Attribution License (CC BY) 4.0 https://creativecommons.org/licenses/by/4.0/
